Qualit-E-SpeakPharma-Insert
X

Find Drugs for Trauma (Emergency, Injury, Surgery) in Phase II Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LB1148

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2020

            Details:

            Data demonstrate efficacy on an approvable endpoint that may also result in substantial cost savings based on reductions ICU and hospital length of stay.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nangibotide

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Roche Diagnostics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 21, 2020

            Details:

            Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PB2452

            Therapeutic Area: Trauma (Emergency, Injury, Surgery)

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: SFJ Pharmaceuticals

            Deal Size: $120.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 10, 2020

            Details:

            The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.